A. Shah, M. Suarez-almazor, and M. E. , Adverse events associated with immune checkpoint blockade in patients with Cancer: a systematic review of case reports, PLOS ONE 29 juill, vol.11, issue.7, p.160221, 2016.

H. Izzedine, C. Mateus, C. Boutros, C. Robert, P. Rouvier et al., Renal effects of immune checkpoint inhibitors, Nephrol Dial Transplant 26 déc, p.382, 2016.

F. B. Cortazar, K. A. Marrone, M. L. Troxell, K. M. Ralto, M. P. Hoenig et al., Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int sept, vol.90, issue.3, pp.638-685, 2016.

F. Fadel, K. E. Karoui, and B. Knebelmann, Anti-CTLA4 antibody-induced lupus nephritis, N Engl J Med, vol.9, issue.2, pp.211-213, 2009.

A. Kitchlu, W. Fingrut, C. Avila-casado, C. T. Chan, M. Crump et al., Nephrotic syndrome with Cancer immunotherapies: a report of 2 cases, Am J Kidney Dis, vol.70, issue.4, pp.581-586, 2017.

J. C. Jennette, R. J. Falk, P. A. Bacon, N. Basu, M. C. Cid et al., 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides, Arthritis Rheum janv, vol.65, issue.1, pp.1-11, 2013.

F. Maritati, F. Iannuzzella, M. P. Pavia, S. Pasquali, and A. Vaglio, Kidney involvement in medium-and large-vessel vasculitis, J Nephrol août, vol.29, issue.4, pp.495-505, 2016.

V. Agrawal, G. M. Crisi, D. 'agati, V. D. , and F. Bj, Renal sarcoidosis presenting as acute kidney injury with granulomatous interstitial nephritis and Vasculitis, Am J Kidney Dis 1 févr, vol.59, issue.2, pp.303-311, 2012.

M. Maanaoui, C. Saint-jacques, V. Gnemmi, M. Frimat, A. Lionet et al., Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma, Medicine, issue.1, p.96, 2017.

A. Daxini, K. Cronin, and A. G. Sreih, Vasculitis associated with immune checkpoint inhibitors-a systematic review, Clin Rheumatol sept, vol.37, issue.9, pp.2579-84, 2018.

B. L. Goldstein, L. Gedmintas, and D. J. Todd, Drug-associated polymyalgia Rheumatica/Giant cell arteritis occurring in two patients after treatment with Ipilimumab, an antagonist of CTLA-4: concise communication, Arthritis Rheumatol mars, vol.66, issue.3, pp.768-777, 2014.

A. C. Shirali, M. A. Perazella, and S. Gettinger, Association of Acute Interstitial Nephritis with Programmed Cell Death 1 inhibitor therapy in lung Cancer patients, Am J Kidney Dis août, vol.68, issue.2, pp.287-91, 2016.

H. Izzedine, V. Gueutin, C. Gharbi, C. Mateus, C. Robert et al., Kidney injuries related to ipilimumab, Invest New Drugs août, vol.32, issue.4, pp.769-73, 2014.

M. A. Perazella, Checkmate: kidney injury associated with targeted cancer immunotherapy, Kidney Int. sept, vol.90, issue.3, pp.474-480, 2016.

L. Kamesh, J. M. Heward, J. M. Williams, S. Gough, K. Chavele et al., CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis, Rheumatology 1 déc, vol.48, issue.12, pp.1502-1507, 2009.

M. C. Slot, M. G. Sokolowska, K. G. Savelkouls, R. Janssen, J. Damoiseaux et al., Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis, Clin Immunol juill, vol.128, issue.1, pp.39-45, 2008.

H. Shafqat, T. Gourdin, and A. Sion, Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy, Semin Oncol, 2018.

D. Sur,

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations